

## Anti-MADD Antibody

### ORDERING INFORMATION

**Catalog No.:** 1150

**Size:** 100 ug IgG in PBS, pH 7.4, purified by immunoaffinity chroma-tography.

### BACKGROUND

MAP kinase-activating death domain protein (MADD) was initially identified as the type 1 tumor necrosis factor receptor (TNFR1). Overexpression of MADD activates MAP kinases ERK and JNK and induces the phosphorylation of cytosolic phospholipase A2. MADD shares 98% homology with DENN (differentially expressed in neoplastic vs. normal cells) which was recently identified as a substrate for c-jun N-terminal kinase 3 (JNK3). MADD has greater than 94% homology with a GDO/GTP exchange protein, Rab3-GEP, and it is 87% homologous with KIAA0358, a brain protein of unknown function. Identification of MADD as a component of the TNFR1 signalling complex and the similarity between MADD and Rab3-GEP provides a connection between TNFR1 activation and downstream MAP kinase activity through a guanine-nucleotide exchange protein.

*For in vitro investigational use only. Not for use in therapeutic or diagnostic procedures.*

### SPECIFICATION SUMMARY

**Antigen:** Peptide corresponding to aa 1570-1588 of human MADD. This peptide sequence is identical to that of DENN and differs by one amino acid with rat GDP/GTP exchange protein RAB3-GEP.

**Host Species:** Rabbit

**Stabilizers:** None

**Preservatives:** 0.02% sodium azide.

### SPECIFICITY

This antibody recognizes human and mouse MADD (200-220 kD).

### APPLICATIONS

*Immunoblotting* : use at 1:250-1:500 dilution.

*Positive control:* Whole cell lysate from HeLa or NIH3T3 cells.

### DILUTION INSTRUCTIONS

Dilute in PBS or medium which is identical to that used in the assay system.

### STORAGE AND STABILITY

This antibody is stable for at least one (1) year at -20°C. Avoid multiple freeze-thaw cycles.